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Our previous studies have shown that microRNA-383 (miR-383) expression is downregulated in the testes of infertile men with
maturation arrest (MA). However, the underlying mechanisms of miR-383 involved in the pathogenesis of MA remain unknown.
In this study, we showed that downregulation of miR-383 was associated with hyperactive proliferation of germ cells in patients
with mixed patterns of MA. Overexpression of miR-383 in NT2 (testicular embryonal carcinoma) cells resulted in suppression of
proliferation, G1-phase arrest and induction of apoptosis, whereas silencing of miR-383 reversed these effects. The effects of
miR-383 were mediated through targeting a tumor suppressor, interferon regulatory factor-1 (IRF1), and miR-383 was negatively
correlated with IRF1 protein expression in vivo. miR-383 inhibited IRF1 by affecting its mRNA stability, which subsequently
reduced the levels of the targets of IRF1, namely cyclin D1, CDK2 and p21. Downregulation of IRF1 or cyclin D1, but not that of
CDK2, enhanced miR-383-mediated effects, whereas silencing of p21 partially inhibited the effects of miR-383. Moreover,
miR-383 downregulated CDK4 by increasing proteasome-dependent degradation of CDK4, which in turn resulted in an inhibition
of phosphorylated retinoblastoma protein (pRb) phosphorylation. These results suggest that miR-383 functions as a negative
regulator of proliferation by targeting IRF1, in part, through inactivation of the pRb pathway. Abnormal testicular miR-383
expression may potentiate the connections between male infertility and testicular germ cell tumor.
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Infertility affects 10–15% of couples who are trying to
conceive, and half of the cases are due to male factors.
1
Despite several decades of efforts to elucidate the etiological
mechanism of male infertility, most cases are idiopathic.
Furthermore, patients with unexplained nonobstructive
azoospermia (NOA), especially men with maturation arrest
(MA, a cause of NOA), usually have a signiﬁcantly lower
sperm retrieval rate and a clinical pregnancy rate.
2 Therefore,
elucidating the underlying pathogenesis of MA may help to
improve treatment outcomes in these patients.
Spermatogenesis is an elaborate process involving the
development of spermatogonial stem cells to highly differ-
entiated spermatozoon, including the stages of actively
proliferating spermatogonia and meiotic spermatocytes.
Some histological studies have suggested the existence of
accelerated germ cell apoptosis
3 and decreased mitotic
activity of spermatogonia
4 in infertile men with MA at the
spermatocyte stage. However, a recent study has shown
normal active spermatogonia in testes arrested at the
pachytene stage.
5 In these cases, spermatogenic failure
may be due to meiotic impairment, such as impaired
chromosome synapsis and decreased meiotic recombina-
tion.
6,7 These histological ﬁndings demonstrate various
patterns of spermatogonial proliferation in men with MA.
However, the molecular mechanisms regulating germ cell
proliferation remain poorly understood.
A signiﬁcant feature of mammalian spermatogenesis is that
numerous mRNAs in differentiating germ cells undergo
posttranscriptional and translational regulation.
8 microRNAs
(miRNAs),afamilyofsmallnoncodingRNAs(typically19–23nt),
post-transcriptionally regulate gene expression through
base pair binding to 30-untranslated region (30 UTR)
sequences of target mRNAs.
9 Several studies have indicated
that miRNAs could have an important role during spermato-
genesis. For example, the loss of Dicer1 (an RNase III
enzyme required for miRNA processing) in primordial germ
cells and spermatogonia resulted in defective proliferation;
10
although in Dicer-deleted testis, spermatogenesis was
arrested at an early stage during proliferation and/or
early differentiation,
10,11 miR-372 and miR-373 have been
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12 However, little is known about the mechanisms
of miRNAs in the regulation of mammalian spermatogenesis.
Recently, we have identiﬁed many deregulated miRNAs in
testicular tissues of NOA patients with MA.
13 miR-383, the
expression of which is restricted to the spermatogonia and
early spermatocytes,exhibited a signiﬁcant downregulation of
gene expression in MA patients.
13 These ﬁndings suggest
thatmiR-383 mayactonearlystagesofspermatogenesisand
thus may regulate germ cell proliferation or death. In this
study,miR-383 wasfunctionallycharacterized inthetesticular
embryonal carcinoma cell line NTERA-2 (NT2) and during
spermatogenesis by identifying its target genes.
Results
Hyperactive proliferation of germ cells in patients with
mixed patterns of MA. Germ cell proliferation and
apoptosis were determined with immunohistochemical
expression of proliferating cell nuclear antigen (PCNA) and
in situ DNA 30-end labeling (terminal deoxy-nucleotidyl
transferase-mediated digoxigenin-dUTP nick-end labeling,
TUNEL) in the testes of infertile men with mixed patterns of
MA, respectively. As shown in Figure 1a, positive TUNEL
staining was detected predominantly in spermatogonia and
spermatocytes. Compared with normal controls, the rate of
germ cell apoptosis in testicular biopsy specimens obtained
from MA patients was slightly upregulated (Table 1).
However, the difference between the groups did not reach
statistical signiﬁcance (P¼0.21). Unexpectedly, most of the
seminiferous tubules in all seven of MA patients exhibited
high immunoreactivity for PCNA in the nuclei of spermato-
gonia and primary spermatocytes (Figure 1b and Table 2).
Furthermore, real-time PCR results also suggested the
upregulation of PCNA mRNA in some patients with MA
(Figure 1c), although specimens obtained from men with
the Sertoli-cell-only (SCO) syndrome showed no PCNA-
immunopositive staining (Figure 1b). These results indicate
that some human spermatogenic failure could be due to
hyperactive proliferation of germ cells.
It is reported that spermatogenic impairment is associated
with the presence of immature Sertoli cells.
14 We then
examined the immunohistochemical expression of cytoker-
atin-18 (CK-18, a marker of immature or undifferentiated
Sertoli cells) in testicular tissues of infertile men with mixed
patterns of MA. Histological analysis revealed remarkable
expression of CK-18 in SCO tubules (Figure 1d). Only the
residual expression of the marker was demonstrated in
adjacent tubules showing arrest of spermatogenesis at the
level of spermatogonia or primary spermatocytes, as well as
normal spermatogenesis (Figure 1d). These results suggest
that in patients with mixed patterns of MA, spermatogenic
arrest is intrinsic to the germ line without affecting Sertoli cell
differentiation.
Downregulation of miR-383 was associated with
enhanced proliferative activity of germ cells in MA
patients. The expression of miR-383 in testicular biopsy
specimens was performed by in situ hybridization (ISH) and
real-time PCR. In seminiferous tubules with normal
spermatogenesis, the miR-383 expression was predomi-
nantly found in spermatogonia and primary spermatocytes
(Figure 1e). Consistent with the miRNA microarray results,
13
miR-383 was decreased signiﬁcantly in testicular specimens
with MA (Figure 1e). In addition, real-time PCR results also
revealed a signiﬁcant downregulation of miR-383 expression
in testes obtained from all ﬁve NOA patients compared with
normal controls (Figure 1f). This downregulation may be
exclusive for these patients, as miR-383 was not altered in
infertile patients with hypospermatogenesis (Supplementary
Figure 1). These data indicate that the downregulation of
miR-383 is associated with increased spermatogonial
proliferation of MA patients.
To determine whether the downregulation of miR-383
occurs at the level of transcription, the expression of primary
miR-383 gene transcripts (pri-miR-383) in the same NOA
patientswasexamined.FouroutofﬁveNOApatients(A2–A5)
with downregulated mature miR-383 expression also showed
a signiﬁcant decrease in pri-miR-383 levels (Figure 1g).
Asigniﬁcantcorrelationbetweenthelevelsofpri-miR-383and
mature miR-383 in these four cases was identiﬁed
(r¼0.8802, Po0.05; Figure 1h), indicating that the miR-383
expression is mainly regulated at the transcriptional level.
However, one case (A1) displayed much higher levels of
pri-miR-383 than did normal controls (Figure 1g), suggesting
an additional layer of post-transcriptional regulation of miR-
383 expression.
Theeffects of miR-383 onNT2 cell survivalwere evaluated.
Overexpression of miR-383 by transfecting the synthetic
miR-383 mimic into NT2 cells not only signiﬁcantly decelerated
cell proliferation (Figure 2a) but also induced G1 cell-cycle
arrest (Figure 2b) and apoptosis (Figure 2c). Conversely,
inhibition of endogenous miR-383 with antisense oligonucleo-
tides resulted in a signiﬁcant elevation in cell proliferation
(Figure 2d), a decrease in cell population in the G1 phase
(Figure 2e) and suppression of basal apoptosis (Figure 2f).
IRF1 is a direct target of miR-383. A potential target of
miR-383, interferon regulatory factor-1 (IRF1), is predicted by
the TargetScan database. The 30 UTR of IRF1 mRNA
harbors a putative miR-383-binding site, which is
evolutionarily conserved in vertebrates (Figure 3a).
To determine whether IRF1 is a true target of miR-383,
NT2 cells were transfected with miR-383 mimic/control or
miR-383 inhibitor/control. Both IRF1 protein (Figures 3b and
c) and IRF1 mRNA (Figure 3d) expressions were signiﬁcantly
decreased in miR-383-transfected NT2 cells than in control
cells, whereas knockdown of miR-383 increased IRF1
protein expression.
To validate whether the IRF1 gene is a direct target of
miR-383, we constructed Renilla luciferase reporters contain-
ing either the wild-type (WT) full-length 30 UTR or the mutant
forms of seeding sites. Cotransfection of the miR-383 mimic
and the reporters into 293T cells resulted in an B45%
decrease in luciferase activity, whereas inhibition of miR-383
expression increased the reporter activity (Figure 3e). On the
other hand, mutation of seed sequences abolished the
silencing effects of miR-383 (Figures 3a and e). Taken
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Cell Death and DiseaseTable 1 Apoptosis in the seminiferous tubules of the testes of MA patients
Number of tissues One site Two sites More than two sites Total
Normal 2 0.07±0.06 0.00±0.00 0.02±0.02 0.09±0.04
Maturation arrest 6 0.11±0.03 0.07±0.02 0.55±0.11 0.73±0.14
P-value 0.43 0.27 0.18 0.21
Apoptosis of testicular germ cells was determined by TUNEL assay. The number of seminiferous tubules containing 1, 2 or 42 apoptotic spermatogonia per weaning
the total number of tubules was deﬁned as the apoptotic rate of 1 site, 2 sites or 42 sites, respectively. The total number of tubules containing apoptotic
spermatogonia per weaning the total number of tubules of the specimen was deﬁned as the total apoptotic rate. Data are shown as mean±S.E.M.
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Figure1 DownregulationofmiR-383expressionisassociatedwithhyperactiveproliferationofgermcellsinMApatients.(a)Apoptoticgermcellsintesticularspecimensof
normal controls and MA patients were identiﬁed by the TUNEL assay. Arrowheads indicate TUNEL-positive cells. (b) Proliferating germ cells were determined by
immunohistochemical staining for PCNA. Scale bar: 13mm. (c) The expression of PCNA mRNA in the testes of normal controls (N1) and MA patients(A1–A5) was examined
by real-time PCR in triplicate. (d) The state of Sertoli cell differentiation was assessed by immunohistochemical staining for CK-18. (e) Localization of miR-383 in the testes of
normal controls and MA patients by LNA-based miRNA in situ hybridization. Representative hematoxylin and eosin staining, hybridization signals (purple) for miR-383 and
negativecontrols are shown.(f andg) Expressionsof maturemiR-383(panel f)and pri-miR-383 (panel g) inthe testesof normalcontrols (N1) andMApatients(A1–A5)were
examinedby real-timePCR in triplicate.(h) A signiﬁcantpositive correlation was found betweenthelevels of pri-miR-383and maturemiR-383(paneld, r¼0.8802,Po0.05)
Scale bar: 50mm. SPG, spermatogonia; PS, primary spermatocyte; Sp, spermatid. The Ct value for the control samples was arbitrarily set at 1. Data were expressed as
mean±S.E.M. (n¼3). **Po0.01, compared with normal controls
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Cell Death and DiseaseTable 2 Expression of the indicated proteins or miR-383 in human testicular specimens
Testicular tissue (ages)
Gene Cell type N1 (28) N2 (69) A1 (30) A2 (26) A3 (35) A4 (20) A5 (27) A6 (27) A7 (34) A8 (28) A9 (24) A10 (27)
miR-383 — + ND        ND ND ND +
PCNA Spermatogonia +/ 
ND
+/  +++ + /   ++ /  
ND NE
ND
Spermatocyte +/  +/  +++ + /   ++ /  
Spermatid +/  NE NE NE NE NE NE NE
Sertoli cell            
IRF1 Spermatogonia   +/  +   
ND
+/  ++ /   +/ 
ND
Spermatocyte   +/  +   ++ /   +   +/ 
Cyclin D1 Spermatogonia  
ND
  +/  ND + +
ND
Spermatocyte        +
p21 Spermatogonia         +/ 
Spermatocyte         +/ 
CDK2 Spermatogonia     
ND
+/  +
Spermatocyte      +/  +
CDK4 Spermatogonia +/  ++ ++
Spermatocyte +/  ++ ++
P-pRb Spermatogonia +/  ++ + /   +++
Spermatocyte +/  ++ + /   +++
Expressions of the indicated proteins were determined by immunohistochemical analysis. Levels of mature miR-383 were examined by real-time PCR and/or in situ
hybridization. For immunohistochemistry, the presence of nuclear staining for the indicated proteins was regarded as a positive expression, whereas cytoplasmic
staining was regarded as a negative expression. Data are presented as three categories: ( ), no detectable staining or positive staining of up to 5%; (+/ ), positive
staining of 5–40%; (+), positive staining of 40–90% cells. A1–A8, maturation arrest; A9, Sertoli-cell-only syndrome; A10, hypospermatogenesis; N1–N2, normal
control; ND, not detected; NE, not existing
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Figure 2 miR-383 functions as a negative regulator of proliferation in NT2 cells. (a and d) miR-383 repressed cell proliferation. Cell viability was measured by the cell
counting kit-8 assay after transfection with 25, 50 or 100nM mimic negative control (Mimic NC) or miR-383 mimic (panel a) or with 150nM inhibitor negative control (Inhibitor
NC) or miR-383inhibitor (panel d). (b and e) miR-383induced G1-phasearrest. Cell-cycleproﬁles were analyzedusing ﬂow cytometry on cells transfected either with 150nM
miR-383 mimic (panel b) or with 150nM miR-383 inhibitor (panel e). (c and f) miR-383 promoted cell apoptosis. The apoptosis rate was measured using ﬂow cytometry with
Annexin V and PI staining after transfection either with 100nM miR-383 mimic (panel c), or with 150nM miR-383 inhibitor (panel f). Data are presented as means±S.E.M.
(n¼3). *Po0.05, **Po0.01, compared with negative controls
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Cell Death and Diseasetogether, these results demonstrate that miR-383 down-
regulates IRF1 directly by decreasing mRNA stability.
To verify whether IRF1 induced phenotypes associated
with miR-383 function, we speciﬁcally silenced IRF1 (si-IRF1)
in NT2 cells by using RNA interference (RNAi). As expected,
knockdown of IRF1 (Figure 4a) led to a signiﬁcantly
decreased cell proliferation in a dose-dependent manner
(Figure 4b), accumulation of cells in the G1 phase (Figure 4c)
and induction of apoptosis (Figure 4d). Furthermore, com-
pared with NT2 cells transfected with the miR-383 mimic,
cotransfection of si-IRF1 and the miR-383 mimic into
cells resulted in a much more decreased cell proliferation
(Figure 4e), a more increased G1-phase population
(Figure 4f) and a higher apoptotic rate (Figure 4g). These
results demonstrate that IRF1, at least in part, mediates the
effects of miR-383 on cell proliferation, cell-cycle regulation
and apoptosis.
As described in this study, IRF1 might exhibit a
pro-mitogenic role in NT2 cells. However, in general, IRF1
had an anti-mitogenic role in most other cell lines.
15 To test
this hypothesis, NT2 cells were growth arrested by serum
starvation. As shown in Figure 4h, the IRF1 protein was
markedly elevated within 2h after serum stimulation of
growth-arrested NT2 cells, just the time point when the IRF1
protein rapidly declined in NIH3T3 cells.
16 Meanwhile, both
miR-383 mimic and si-IRF1 inhibited serum-inducible IRF1
protein expression (Figure 4i). These observations suggest
that,besidesitsfunctionasananti-mitogenicfactor,IRF1also
exhibits a pro-mitogenic role in NT2 cells.
miR-383 expression correlates negatively with the IRF1
protein in vivo. To further validate the regulatory
relationship between miR-383 and its target IRF1 in vivo,
expressions of miR-383 and IRF1 protein were identiﬁed in
the normal human/mouse testis and in human infertile testis.
First, the developmental changes of miR-383 and IRF1
protein expression in the mouse testis were surveyed by real-
time PCR and western blot analysis, respectively. The
miR-383 expression was high at birth, then gradually
decreased until 14 days postpartum (dpp) (except for an
increase at 8dpp), and became stable from 3 weeks onwards
(Figure 5a). ISH analysis showed that miR-383 was mainly
expressed in spermatogonia and primary spermatocytes,
which was consistent with the results obtained in the human
testis (Figure 5b). The IRF1 expression was increased soon
after birth, peaked at 5dpp and then gradually declined
(Figures 5c and d). Immunocytochemical localization
demonstrated that IRF1 was predominantly expressed in
the cytoplasm of spermatogonia (Figure 5e). However, a
nuclear accumulation of IRF1 was observed at 5dpp
(Figure 5e). Furthermore, a signiﬁcant negative correlation
mmu-miR-383
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Cell Death and Diseasebetween the expression of miR-383 and IRF1 at 0–8dpp was
found (r¼ 0.9861, Po0.05; Figure 5f).
Second, the IRF1 expression in human testicular speci-
mens of two controls and seven MA patients was analyzed by
immunohistochemistry. As showed in Figure 5g and Table 2,
IRF1 was also detected in a very small proportion of
spermatogonia and restricted to the cytoplasm in controls.
However, all MA patients but one (case A2) showed
signiﬁcantly higher signal intensity in the nucleus of both
spermatogonia and primary spermatocytes, or in either of
them (case A7 for spermatogonia, case A3 for primary
spermatocytes). Meanwhile, four out of the ﬁve cases of
testiculartissuesthathadreducedmiR-383levels,showedan
elevatedIRF1expression(Table2).Theothertwocaseswere
not examined for miR-383 levels as we did not have enough
tissues to analyze. These observations corroborate the
negative correlation between the expression of miR-383 and
IRF1 in MA patients.
miR-383 represses IRF1-targeted cell cycle-related
genes. It is well known that the transcription factor IRF1
exerts multiple effects by activating a set of target genes,
depending on the cell type and on the speciﬁc stimuli.
17
We next examined the effects of IRF1/miR-383 on the
expressions of known IRF1 target genes involved in the
regulation of cell apoptosis, cell cycle and DNA repair. Our
results revealed that mRNA (Figure 6a) and protein
(Figure 6b) levels of three cell cycle-related genes, namely
Cyclin D1,
18 CDK2
19 and p21,
20 were all lower in NT2
cells transfected with si-IRF1 than in cells transfected
with negative controls (NCs). Similarly, the miR-383 mimic
clearly decreased mRNA and protein levels of these
three genes (Figures 6c and d), whereas knockdown of
miR-383 induced their mRNA and protein expressions
(Figures 6c and d).
We were then interested in identifying a major gene
responsible for miR-383-mediated proliferation control in
NT2 cells. Protein expressions of cyclin D1, CDK2 and p21
were analyzed after serum stimulation of growth-arrested
cells. As shown in Figure 7a, mitogen stimulation markedly
induced cyclin D1 and p21 expression, but CDK2 levels
remained constant. Only cyclin D1 was inhibited by the
miR-383 mimic or si-IRF1. In addition, although si-cyclin D1,
si-CDK2 and si-p21 (Figure 7b) all resulted in inhibition of
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Figure 4 Silencing of endogenous IRF1 enhances miR-383-mediated effects on cell cycle and apoptosis in NT2 cells. (a) The efﬁcacy of IRF1 siRNA was evaluated by
western blotting after 48h transfection with either siRNA negative control (si.NC) or IRF1 siRNA (si-IRF1). (b–d) Knockdown of IRF1 inhibited cell proliferation (panel b),
inducedG1-phasearrest(panelc) andactivatedapoptosis(paneld). Cellviability(panel b)was measuredby thecellcountingkit-8assayaftertransfectionwith 5,10,20, 30,
50,100nMsi.NCor si-IRF1.Proportionsof cellsintheG1, S,andG2/Mphasesof thecellcycle(panelc)andapoptoticrates(paneld)weredeterminedusingﬂowcytometry.
(e–g) Silencingof IRF1 enhancedmiR-383-induced proliferationsuppression(panel e), G1-phasearrest (panel f) and apoptosis(panel g). Cell viability, cell-cycleproﬁlesand
apoptoticrateswereanalyzedaftercotransfectionwith100nMmiR-383mimicand30nMsi-IRF1intoNT2cells.(h)IRF1wasinducedrapidlybyserum.NT2cellsweregrowth
arrested by serum starvationfor 24h and then harvested for western blot analysisat the indicatedtime points after serum stimulation. Untreated cells were also included as a
control (Exp). (i) Overexpression of miR-383or silencing of IRF1 inhibited serum-inducibleIRF1 protein expression. Cells were transfected with the indicated oligonucleotides
afterserumstarvationfor6handgrowtharrestedforafurther18h.Forwesternblotanalysis,cellswereharvested2hafterserumstimulation.SFM,serum-freemedium.Error
bars indicate S.E.M. (n¼3). *Po0.05, **Po0.01, ***Po0.001, compared with negative controls
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Cell Death and Diseaseproliferation (Supplementary Figures 2a and b), only knock-
down of cyclin D1 caused G1-phase arrest in NT2 cells
(Supplementary Figures 2c and d). Furthermore, overexpres-
sion of cyclin D1 partly rescued miR-383-induced inhibition
of proliferation (Figure 7c). These results suggested that
cyclin D1 might be the major gene responsible for miR-383-
mediated antiproliferative effects in NT2 cells.
Interestingly, contrary to the role of cyclin D1 in NT2 cells,
p21 promoted G1/S transition (SupplementaryFigures2candd).
In addition, knockdown of p21 partly inhibited miR-383-
induced G1-phase arrest, but si-cyclin D1 dramatically
enhanced the effects of miR-383 (Figure 7d). Similarly,
silencing of cyclin D1 and silencing of p21 resulted in a slight
increase and decrease in apoptosis rates, respectively
(Figure 7e).
miR-383 inhibits pRb phosphorylation and CDK4 protein
levels. The assembly of cyclin D1–CDK4–p21 complex is
required for phosphorylated retinoblastoma protein (pRb)-
mediated G1/S transition.
21 As described above, miR-383
represses the expression of two members of this complex,
cyclin D1 and p21, which leads us to ask whether miR-383
has a role in regulating the activity of cyclin D1–CDK4–p21
complex. We ﬁrst examined the effects of miR-383 on
pRb phosphorylation using speciﬁc antibodies recognizing
pRb phosphorylated on Ser
249/Thr
252. Phosphorylations of
Ser
249/Thr
252 in vitro are preferentially catalyzed by cyclin
D1–CDK4 complex.
22 The results revealed that both
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Cell Death and DiseasemiR-383 mimic and si-IRF1 inhibited serum-inducible pRb
phosphorylation (Figure 7f).
Second, immunoﬂuorescenceshowed thatneither the miR-
383 mimic nor si-IRF1 affected the nuclear localization of
cyclin D1 and CDK4 in NT2 cells (Supplementary Figures 3a–c).
However, although silencing of IRF1 did not affect CDK4
protein levels (Figure 7g), the miR-383 mimic repressed
CDK4 expression(Figure 7g) without a signiﬁcant decrease in
CDK4 mRNA levels (Supplementary Figure 4a). We then
explored the possibility that CDK4 might also be a target of
miR-383.However,luciferaseassayshowedthatthemiR-383
mimic did not inhibit luciferase activity of a reporter vector
containing the full-length CDK4 30 UTR (Supplementary
Figure 4b).
As miR-383 affects neither CDK4 transcription nor CDK4
mRNA stability, we speculate whether miR-383 induces
degradation of CDK4 through a proteasome-dependent
pathway. As shown in Figure 7h, treatment with the protea-
some inhibitor MG-132 restored CDK4 expression that
was downregulated by miR-383. These results conﬁrm that
miR-383 suppresses CDK4 protein expression by promoting
proteasome degradation of CDK4.
Widespread upregulation of P-pRb expression in MA
patients. To further understand the role of the above-
mentioned miR-383-pRb pathway in spermatogenesis, the
expression of cyclin D1, p21, CDK2, CDK4 and phospho-
rylated pRb (P-pRb) was analyzed in testicular specimens
of MA patients. The immunohistochemical expression
patterns of these proteins are summarized in Table 2. In
germ cells in normal controls, expressions of cyclin D1, p21
and CDK2 were nearly undetectable, whereas both diffuse
immunostaining for P-pRb and distinct staining pattern for
CDK4 were detected in the nucleus of spermatogonia,
spermatocytes and round spermatids (Figure 8). Although
nuclear localization of staining for all these proteins was
higher in some seminiferous tubules of MA patients
characterized by the downregulation of mature miR-383
(Table 2), only enhanced nuclear staining for P-pRb
was identiﬁed in all MA patients studied. For example, one
Serum (2 h)
30
30
30
20
30
kDa
*
P = 0.09
R
e
l
a
t
i
v
e
 
C
e
l
l
P
r
o
l
i
f
e
r
a
t
i
o
n
1.2
1
0.8
0.6
0.4
0.2
0
+
+
+ +
+
+
-
-
-
-
-
-
Mimic NC
miR-383 mimic
pcDNA3.1
pcDNA3.1/Cyclin D1
* P = 0.08
* P = 0.29
Annexin V
Annexin V+PI
%
 
P
o
s
i
t
i
v
e
 
a
p
o
p
t
o
t
i
c
 
c
e
l
l
s 50
40
30
20
10
0
+-+- +-+
- + - + - +
DMSO
Mimic NC +
+
+
+
-
-
-
- miR-383 mimic
CDK4
GAPDH
MG-132
kDa
30
30
- +
si.NC si-Cyclin D1
30
30
si.NC si-p21
- mimic NC
miR-383 mimic
CDK4
GAPDH
si.NC +
-
-
-
+
+
-
-
-
si-Cyclin D1
si-CDK2
Cyclin D1
CDK2
GAPDH
GAPDH
p21
20
30
30
40
30
p21
CDK2
Cyclin D1
IRF1
GAPDH
Serum (24 h)
30
120 P-pRb
GAPDH
**
*
Mimic NC
miR-383 mimic
si.NC si-Cyclin D1 si.NC si-p21
C
e
l
l
 
c
y
c
l
e
 
(
%
G
1
)
100
80
60
40
0
20
kDa SFM Mimic NC
miR-383 mimic
si.NC
si-IRF1
kDa Mimic NC
miR-383 mimic
si.NC
si-IRF1
Inhibitor NC
miR-383 inhibitor
SFM kDa Mimic NC
miR-383 mimic
si.NC
si.IRF1
kDa si-NC
si-p21
Figure 7 The pRb pathway mediated miR-383-induced phenotype in NT2 cells. (a) Cells were treated as in Figure 4i. For western blotting analysis of the indicated
proteins, cells were harvested 2h after serum stimulation of growth-arrested cells. (b) The efﬁcacy of siRNAs for cyclin D1, CDK2 and p21 was evaluated by western blot.
(c) Cyclin D1 partly rescued NT2 cells from growth inhibition by miR-383. Twenty-four hours after transfection with 100nM miR-383 mimic, cells were further transfected with
0.1mg cyclin D1 expression vector (pcDNA3.1/cyclin D1) for 24h and then subjected to cell viability assay. (d and e) Effects of knockdown of cyclin D1 or p21 on miR-383-
induced G1-phase arrest (panel d) and apoptosis (panel e). NT2 cells were cotransfected with the miR-383 mimic and the indicated siRNAs. (f) Immunoblot analysis of
phosphorylation of pRb using an antibody speciﬁc for phosphorylated Ser
249/Thr
252 (P-pRb). Cells were treated as in Figure 4i. For western blotting analysis, cells were
harvested 24h after serum stimulation of growth-arrested cells. (g and h) The protein level of CDK4 was determined by western blotting 24h after transfection with the
indicated oligonucleotides (panel g) or cotreatment of the miR-383 mimic with 20mM of MG-132 or DMSO (panel h). SFM, serum-free medium. Error bars indicate S.E.M.
(n¼3). *Po0.05, **Po0.01, compared with negative controls
miR-383 targets IRF1 to inhibit cell proliferation
J Lian et al
8
Cell Death and Diseasecase (A1) showed enhanced nuclear staining for P-pRb, but
could not detect the expression of cyclin D1 in the nucleus
(Table 2); in particular, one case (A6) with downregulated
miR-383 expression and upregulated IRF1 protein expres-
sion in the testis, exhibited a markedly enhanced nuclear
staining for all these proteins (Figure 8). These results
indicate that dysregulation of the miR-383-mediated
pRb pathways may contribute to spermatogenic failure in
MA patients.
Discussion
The completion of spermatogenesis depends on not only the
proliferative activity of spermatogonia but also the loss of
germ cells during meiosis and spermiogenesis.
4 In this study,
we found that downregulation of miR-383 and upregulated
IRF1 expressions are associated with increased mitotic
activity of germ cells in patients with mixed patterns of MA.
In addition, the miR-383-IRF1-pRb pathways are identiﬁed in
the regulation of NT2 cell survivals. We provide, for the ﬁrst
time, mechanistic insights into the role of miR-383 in
spermatogenesis and in NT2 cell proliferation.
We have reported that miR-224 can promote TGF-b1-
induced germ cell proliferation,
23 and that miR-383 might
regulate germ cell proliferation/death at early stages of
spermatogenesis.
13 In this study, miR-383 acts as a negative
regulator of proliferation in NT2 cells; in addition, down-
regulationofmiR-383ingermcellswasobservedinallourMA
patients. These results indicate that miR-383 could contribute
to spermatogenic arrest caused by the dysregulation of germ
cell proliferation. Furthermore, miR-383 was also expressed
at high levels in primary spermatocytes from normal human
testes, suggesting a role for miR-383 in meiosis. We found
that both CDK2 and CDK4 were regulated by miR-383 in NT2
cells, whereas CDK4 and CDK2 were colocalized with RPA
(a marker for early meiotic recombination nodules) and MLH1
(a marker for late recombination nodules) on the mouse
synaptonemal complex, respectively.
24 Whether miR-383 is
involved in meiotic recombination in human germ cells
requires further investigation.
miRNAs are known to control diverse biological processes
through the regulation of target genes. In this study, we
demonstrate thatIRF1 isa downstreamtargetof miR-383 and
mediates miR-383-induced antiproliferative effects in vitro.
AninversecorrelationbetweenmiR-383andIRF1proteinlevels
was also identiﬁed in the testes of 80% (4/5) of MA patients.
IRF1 has been identiﬁed as a tumor suppressor and tumor
susceptibility gene. It can inhibit cell growth, cause G1-phase
cell-cycle arrest and promote apoptosis.
15,25 However, in this
study, we suggest a pro-mitogenic role for IRF1 in NT2 cells.
In addition, MA patients with reduced levels of miR-383 and
high proliferative activity of germ cells showed upregulation of
IRF1. These results indicate that IRF1 may also act as a
survival factor for germ cells both in vitro and in vivo. This
novel role has also been demonstrated in vivo by Chapman
et al.,
26 who observed that the loss of IRF1 in mice resulted in
accelerated apoptosis of epithelial cells leading to premature
involution after weaning.
Over the past few years, several studies have focused on
the role of IRF1 in the immune system and in cancer.
15,17,25,27
However, a function for IRF1 in gametogenesis has not yet
been investigated. In this study, IRF1 expression was
gradually increased after birth and reached a maximum at
5dpp, at which time spermatogonia start to undergo sequen-
tial mitotic divisions before the initiation of meiosis.
28 IRF1
levels were also markedly elevated soon after serum
stimulation of growth-arrested NT2 cells. On the contrary,
miR-383 was decreased after birth and reached the lowest
levels at 14dpp, at which time testicular cell proliferation and
expansion occur at the highest level.
28 Furthermore, a
signiﬁcant negative correlation between the expression levels
of mature miR-383 and IRF1 protein was observed in
the mouse testis from 0 to 8dpp, further indicating that
IRF1 is a target of miR-383. These results suggest that the
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Cell Death and Diseasepro-mitogenic role of IRF1 may be limited to only the
spermatogonial stage.
Notably, we also found that miR-383 inﬂuenced the
expression of proteins required for the G1/S transition phase,
the cyclin D1–CDK4–p21 complex and CDK2. Moreover, the
downregulation of miR-383 expression is accompanied by
enhanced nuclear staining for P-pRb in all MA patients. In the
early G1 phase, the cyclin D1–CDK4 complex partially
activates pRb by phosphorylation, resulting in the inhibition
of pRb function; in the late G1 phase, CDK2 complexed
with cyclin E further phosphorylates pRb to complete its
inactivation and allows the cell to enter the S phase.
29,30
Phosphorylations of pRb mediated by the cyclin D1–CDK4
complex and CDK2 are required for cell-cycle re-entry.
31 Our
data indicate that defection in the miR-383-pRb pathway may
be a cause for proliferative dysfunction of germ cells in MA
patients.
Cyclin D1 has an important role in G1/S phase transition.
32
In this study, we found that among the targets of IRF1, cyclin D1
is a major regulator responsible for miR-383-mediated cell-
cycleeffectsonNT2cells.AlthoughnocyclinD1expressionis
detected in adult human male germ cells in the current study,
as also noticed by other researchers,
33,34 nuclear cyclin D1
expression was observed in germ cells of 75% (3/4) MA
patients. Ikumasa et al.
35 also found that 44.4% (4/9) of MA
patients showed a cyclin D1 expression in germ cells.
Although miR-383-mediated effects were partially dependent
on p21 in vitro, p21 was rarely expressed in the testes of both
MA patients and normal controls, indicating a p21-indepen-
dent pathway mediating spermatogenesis. However, in
contrast to the expression of cyclin D1 and p21, CDK4
expression was observed in the testis of all MA patients and
normal controls. Combined with the observation that adult
germ cells proliferate through a cyclin D1-independent path-
way,
33 our results suggest that the effect of miR-383 on pRb
phosphorylation in the human testis may be mainly mediated
by the activated CDK4 expression.
The existenceof the widespread expressionof P-pRb in the
testes of MA patients indicates a status of ‘physiological
absence of pRb’ in infertile men. The loss of pRb is highly
related to the occurrence of TGCTs.
36,37 Recent reports have
shown strong evidence that infertile men are nearly three
times more likely to develop TGCTs than are those who are
fertile;
38 however, the mechanisms linking infertility and
TGCT remain uncertain.
39 Whether the activated P-pRb
expression accompanied by downregulation of miR-383 in
infertile testes drives the association between infertility and
TGCT is warranted.
In summary, we demonstrate that miR-383 functions as a
negative regulator of cell proliferation by directly targeting
IRF1. Defective miR-383-pRb pathways are associated with
spermatogeneic arrest. The mechanistic studies regarding
the role of miRNAs in spermatogenesis will provide new clues
to treating male infertility or, on the opposite, designing new
male contraceptives. In addition, our results also propose a
potential pathway connecting male infertility with TGCT.
Materials and Methods
Mouseandhumantesticularsamples. ICRmicewereobtainedfromthe
Animal Center, University of Science and Technology of China (USTC, Hefei,
China). All animal experiments were conducted following the guidelines for the care
and use of laboratory animals from the USTC.
Testicular biopsy specimens obtained from 10 patients (aged 20–35 years) with
NOA and from 2 control subjects (aged 28–69 years) were obtained from the First
Afﬁliated Hospital of Anhui Medical University (Hefei, China). Each testicular
specimen was divided into several portions for different experiments. Some tissues
were too small to complete all experiments. The conditions for specimen use are
summarized in Table 2. According to standard pathological criteria, eight patients
with mixed pattern of MA, one patient with hypospermatogenesis and one patient
with SCO syndrome were recruited for this study. The mixed pattern of MA is
characterized by various spermatogenic impairments in adjacent seminiferous
tubules showing both SCO and spermatogenic arrest at the level of spermatogonia
or primary spermatocytes. As normal controls, the optimal study population would
consistofvolunteersofknownfertility,butdifﬁcultiesinacquiringtesticularmaterials
make this impractical. Instead, testicular samples were obtained from patients
undergoing orchiectomy for prostate carcinoma before chemotherapy. None of
them had a history of meiotic defects or infertility, and histological examination
revealed normal spermatogenesis. All patients gave informed consent, and this
study received ethical approval from the Institutional Review Boards of the USTC
and the Anhui Medical University.
Vectors. ThepsiCHECK-2dual luciferase reporter vectorwas kindly provided by
Biliang Zhang (Guangzhou Institute of Biomedicine and Health, Chinese Academy
of Sciences, China), and the pcDNA3.1 vector was kindly provided by Mian Wu
(USTC, China). The cyclin D1 expression vector was constructed by cloning human
cyclin D1 cDNAs into the pcDNA3.1 vector at the BamHI and XhoI sites. For
construction of luciferase reporter plasmids, WT IRF1 30 UTR was obtained by
amplifying a 790-bp 30 UTR fragment of IRF1 harboring the miR-383-binding
site predicted by the TargetScan (http://www.targetscan.org/), whereas mutated
IRF1 30 UTR was generated by PCR-based site-directed mutagenesis. WT and
mutated IRF1 30 UTR, as well as full-length CDK4 30 UTR sequences were inserted
into the XhoI and NotI sites of the psiCHECK-2 reporter vector immediately
downstream of the stop codon of an SV40 promotor-driven Renilla luciferase gene.
Primer sequences are listed in Supplementary Table 1.
Oligonucleotides. siRNA duplex homologs in sequence with the miRNA-383
mimic and miR-383 inhibitor, as well as scramble NCs, were synthesized and
puriﬁedbyShanghaiGene-PharmaCo.(Shanghai,China).ThemiR-383inhibitoris
a single-stranded 2-O-methyl (2-OMe)-modiﬁed oligoribonucleotide fragment
exactly antisense to miR-383. siRNAs (si-IRF1, si-cyclin D1, si-CDK2, si-p21)
were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). For ISH
assay, 50 end digoxigenin-labeled locked nucleic acid (LNA)-modiﬁed DNA
oligonucleotides complementary to mature miR-383 (LNA miR-383) and scramble
NCs (LNA scrambled) were supplied by Exiqon A/S (Vedbaek, Denmark).
Oligonucleotide sequences are provided in Supplementary Table 2.
Histological analysis, immunohistochemistry and ISH. Tissues
weredissectedout,ﬁxedwith4%paraformaldehyde,embeddedinparafﬁnwaxand
sectioned at 4mm. The sections were then used for histological evaluation,
immunohistochemical detection of protein expression and TUNEL assay. For
histological evaluation, sections were stained with hematoxylin and eosin using
standard techniques.
For protein immunolocalization in human testes, sections were microwave
heated in 10mM sodium citrate buffer, pH 6.0 for 10min after deparafﬁnization and
were then treated with 3% H2O2 in phosphate-buffered saline (PBS) containing
0.1% Triton X-100 to inhibit endogenous peroxidase. After blocking nonspeciﬁc-
binding sites with 10% normal donkey serum (Jackson ImmunoResearch Labs Inc.,
West Grove, PA, USA), sections were then incubated with primary antibodies
overnight at 41C and secondary antibodies for 2h at room temperature,
respectively. Immunosignals were visualized using streptavidin–peroxidase and
3, 30-diaminobenzidine (Maixin Bio, Fuzhou, China). The primary and secondary
antibodies used in this study are described in Supplementary Tables 3 and 4,
respectively.
For the detection of apoptosis in tissues, sections were subjected to
biotin–streptavidin–horseradish peroxidase labeling of DNA strand breaks by
TUNEL, using the DeadEnd Colorimetric TUNEL System (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. As a NC, the TdT enzyme was
omitted in parallel reactions.
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Cell Death and DiseaseISH was performed on 10-mm frozen tissue sections using LNA-modiﬁed DNA
probes, as described previously.
13 The probe sequences are listed in
Supplementary Table 2. In brief, 10mm testis biopsy sections obtained from
normal controls and NOA patients were ﬁxed with 4% paraformaldehyde for 15min
at room temperature. To block endogenous alkaline phosphatase activity, slides
were immersedand stirred gently in 0.1M ethanolamine and 2.5% acetic anhydride
for 10min, followed by treatment with 5mg/ml proteinase K for 3min after extensive
washing with PBS. Prehybridizations were performed for 6h in a hybridization oven
at a temperature between 21 and 231C below the reported melting temperature of
the LNAs (571C) with 700ml prehybridization buffer (50% formamide, 5  SSC,
5  Denhardt’s, 200mg/ml yeast RNA, 500mg/ml salmon sperm DNA, 2% Roche
blocking reagents (Roche, Basel, Switzerland) and DEPC-treated water). A 1pmol
probe was added to 150ml denaturizing hybridization buffer (50% formamide, 5 
SSC, 5  Denhardt’s, 200mg/ml yeast RNA, 500mg/ml salmon sperm DNA, 2%
Roche blocking reagents, 0.25% CHAPS, 0.1% Tween and DEPC-treated water).
After denatured at 801C for 5min, hybridization occurred overnight at the
prehybridization temperature-covered glass coverslips. To remove the coverslips,
slidesweresoakedinpre-warmed601C5  SSC.Afterincubationin0.2  SSCat
601Cfor1h,sectionswerewashedinB1solution(0.1MTrispH7.5/0.15MNaCl)at
roomtemperaturefor10min.Afterblockingfor1hin20%sheepserum(SantaCruz
Biotechnology Inc.) diluted with B1 solution, the sections were incubated overnight
at 41C 10% sheep serum containing anti-Digoxigenin-AP FAB fragments (Roche;
1:250). After washing three times for 5min in the B1 solution at room temperature
and equilibrated for 10min in B3 solution (0.1M Tris pH 9.5/0.1M NaCl/50mM
MgCl2), the sections were stained with NBT/BCIP (Roche) overnight at room
temperature. When each probe had yielded a strong signal, or until the NCs began
to show background label, reactions were stopped by washing with PBS. Signals
were visualized under a standard light microscopy.
Cell culture and transfection. NTERA-2 (NT2) and HEK 293T cells were
grown in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal bovine
serum (Life Technologies Inc., Grand Island, NY, USA) and 1% antibiotics
(100Units/ml penicillin and 100mg/ml streptomycin; Life Technologies Inc.) and
cultured at 371C with 5% CO2. Transfection of 293T cells was performed by
Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA). Lipofectamine
RNAiMAX (Invitrogen) and Fugene HD (Roche) were used for the transfection of
oligonucleotides and plasmids into NT2 cells, respectively. The transfection
procedure was performed according to the manufacturer’s instructions. Unless
otherwise indicated, cells were transfected with 30nM siRNAs, 100nM miR-383
mimic or 150nM miR-383 inhibitor. For serum stimulation experiments, NT2 cells
were growth arrested for 24h in serum-free medium and DMEM containing 10%
FBS was then added. Cells were harvested at the indicated time points.
RT-PCR and real-time PCR. Total RNA was extracted using the SV Total
RNAIsolationSystem(Promega),andsemi-quantitativereversetranscriptase(RT)-
PCR was performed using the PrimeScript One-Step RT-PCR Kit Version 2
(TaKaRa Bio Inc., Otsu, Japan). Relative quantiﬁcation in real-time PCR was
performed on ABI Step One System (Applied Biosystems, Foster City, CA, USA),
using the SYBR Premix EX Taq kit (TaKaRa Bio Inc.), following the manufacturer’s
protocols.Forpri-miRNAreal-timePCRanalysis,primersweredesignedtositdown
B170bp 50 and 30 to the predicted miRNA stem loop precursor, as described by
Cai et al.,
40 and the downstream primer was used for RT reaction as well. mRNA
levels were normalized to human b-actin mRNA or mouse GAPDH mRNA. Primer
sequences for RT-PCR and real-time PCR are provided in Supplementary Tables
5 and 6, respectively.
For real-time PCR detection of miR-383, small RNAs were isolated using the
mirPremier miRNA isolation kit (Sigma-Aldrich, St. Louis, MO, USA), and the miR-
383 expression was quantiﬁed using TaqMan miRNA assays (Applied Biosystems)
according to the manufacturer’ instructions. U6 snRNA (Applied Biosystems) was
used for normalization. The threshold cycle (Ct) is deﬁned as the fractional cycle
number at which the ﬂuorescence passes the ﬁxed threshold. Each PCR reaction
was performed in triplicate.
Western blotting. Cells were lysed in RIPA buffer (50mM Tris-HCl, pH 7.4,
150mM NaCl, 1% Triton X-100, 1% sodium dodecyl sulfate, 1% sodium
deoxycholate, 1mM EDTA) together with complete EDTA-free protease inhibitor
cocktail (Roche), 1mM phenylmethylsulfonyl ﬂuoride and phosphatase inhibitors
(5mM sodium orthovanadate). Tissue lysates were prepared using the KeyGen
total protein extraction kit (KeyGEN, Nanjing, China) according to the
manufacturer’s instructions. Protein lysates were resolved by SDS-PAGE,
transferred to Hybond enhanced chemiluminescence (ECL) Nitrocellulose
membrane (Amersham Biosciences, Freiburg, Germany), immunoblotted with
antibodies and visualized by ECL (Kodak, Rochester, NY, USA). Protein levels
were normalized to GAPDH and quantiﬁed using the Scion Image program 4.0.3.2
(Scion Corporation, Frederick, MD, USA). The proteasome inhibitor MG-132 was
purchased from Sigma-Aldrich. The primary and secondary antibodies used for
immunoblotting are listed in Supplementary Tables 3 and 4, respectively.
Cell proliferation assay. Cell proliferation was measured using cell counting
kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan). NT2 cells were plated at
3–5 10
3 cells/well in 96-well plates with 5 replicate wells for each condition.
Forty-eight hours after transfection, 10ml of CCK-8 solution was added to the
medium and then incubated at 371C for 2h. Cell numbers were measured by
measuring the absorbance at 450nm using a 96-well format plate reader (ELx800
Universal Microplate Reader; Biotek Instrument Inc., Highland Park, VT, USA).
Flow cytometric analysis. Cell-cycle regulation and apoptosis were
analyzed using the FACScalibur ﬂow cytometer (BD Biosciences, San Jose, CA,
USA). Data analysis was carried out using WinMDI 2.9 software (The Scripps
Research Institute, La Jolla, CA, USA). For cell-cycle analysis, cells were seeded in
6-well or 12-well plates at 60–70% conﬂuency. Twenty-four hours after transfection
with the indicated oligonucleotides, NT2 cells were harvested, washed in PBS and
ﬁxed overnight in 70% ethanol. The next day, cells were collected, washed in PBS,
incubatedat 371C for 10min with PBS containing100mg/mlRNase A and25mg/ml
propidium iodide (PI) (Sigma-Aldrich) and analyzed by ﬂow cytometry. For cell
apoptosis analysis, cells were seeded in 6-well or 12-well plates at 30–50%
conﬂuency. Cells were harvested at 72h after transfection with 80nM indicated
siRNAs, 100nM miR-383 mimic or 150nM miR-383 inhibitor, stained using the
Annexin V FITC Apoptosis Detection Kit (Beijing Biosea Biotechnology Co., Ltd,
Beijing, China) and PI staining solution, and analyzed by ﬂow cytometry.
Luciferase reporter assay. 293T cells were cotransfected with either
20pmol miR-383 mimic or 30pmol miR-383 inhibitor and 200ng psiCHECK-2
vectors in 24-well plates with three replicate wells for each condition. Luciferase
activity was measured 30h after transfection using the Dual Luciferase Reporter
Assay System (Promega). Renilla luciferase activity was normalized to Fireﬂy
luciferase activity for each transfected well. All experiments were performed
in triplicate.
Immunoﬂuorescence analysis. See Supplementary Methods for details.
Statistics. Student’s t-test was applied to examine the differences among
variables. Data were shown as mean±S.E.M. unless otherwise indicated. The
relationships between pri-miR-383 and mature miR-383 expressions in human
testes, and those between mature miR-383 and IRF1 protein expressions in the
mousetesteswereevaluatedusingPearson’scorrelationanalysis.P-valueso0.05
were considered to be statistically signiﬁcant.
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